Obesity is a disease characterized by excessive accumulation of body fat associated with health problems. Several drugs have been studied for the control of obesity, such as orlistat, which reduces the absorption of dietary lipids through the inhibition of lipases. The inactivated enzyme is unable to hydrolyze triglycerides, the main class of lipids present in the diet, fatty acids and monoglycerides absorbable as well as 30% of ingested fat is excreted in faeces, contributing to weight reduction. This project aims to evaluate changes in lipid composition of erythrocyte membrane and blood plasma resulting from treatment with orlistat. The understanding of these changes not only helps us to investigate changes in metabolic markers, but also provides a guide to clinical management of obesity. So we perform a measurement of cholesterol esters and phospholipids by GC / MS before and during treatment, and the analysis of cholesterol and blood plasma metabolomics, in search of new biomarkers suitable to monitor treatment, both by 1H NMR. Data analysis will be done by analysis of variance (ANOVA) and the NMR spectra of 1H will be submitted to analysis of PCA and PLS-DA in search of new biomarkers.
News published in Agência FAPESP Newsletter about the scholarship: